Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
July 26, 2023 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Vielight Starts Clinical Trial to Study Photobiomodulation Device Treatment for Post-Covid Cognitive Impairment
July 26, 2023 10:33 ET
|
Vielight Inc.
Toronto, Canada, July 26, 2023 (GLOBE NEWSWIRE) -- Vielight Inc. announced it has commenced a new clinical trial in the United States to study how brain stimulation photobiomodulation (PBM)...
$2.34Bn Growth for Mice Model Market Size to Hit 5.4% CAGR with CRISPR Segment Driving Growth During 2022-2028
July 25, 2023 09:19 ET
|
The Insight Partners
Pune, India, July 25, 2023 (GLOBE NEWSWIRE) -- According to Recently Published Report by The Insight Partners, “Mice Model Market Size Report and Forecast to 2028 - COVID-19 Impact and Global...
Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate
July 24, 2023 08:30 ET
|
Dyadic International, Inc.
Dosing of patients completed at the end of FebruaryData Safety Monitoring Board conducted analysis of Day 29 data No major vaccine-related safety concerns for either of the two dose levelsNo Serious...
DHR EQUITY ALERT: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Danaher Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – DHR
July 19, 2023 15:36 ET
|
The Rosen Law Firm PA
NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Danaher...
LEX Diagnostics Appoints Chief Technology Officer
July 18, 2023 03:00 ET
|
LEX Diagnostics
CAMBRIDGE, United Kingdom, July 18, 2023 (GLOBE NEWSWIRE) -- LEX Diagnostics (LEX) today announces the appointment of Dr Heather Danks as its Chief Technology Officer (CTO). The company is...
Kinarus Therapeutics Announces Personnel Change
July 12, 2023 01:00 ET
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, July 12, 2023 – Kinarus Therapeutics Holding AG (“Kinarus”) (SIX: KNRS), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory and...
AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
July 10, 2023 08:05 ET
|
AIM ImmunoTech Inc.
Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 ...
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
July 05, 2023 08:35 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting
June 29, 2023 12:00 ET
|
Kinarus Therapeutic Holding AG
Basel, Switzerland, 29 June 2023. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral,...